2025-12-19 - Analysis Report
Okay, let's break down the analysis of TG Therapeutics (TGTX).

**1. Simple Numbers and Comparison to S&P 500 (VOO)**

*   **TGTX Cumulative Return:** 66.26%
*   **VOO Cumulative Return:** 99.09%
*   **Divergence:** -28.8 (Relative Divergence: 17.8)

**Analysis:**

*   **Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
*   TGTX has underperformed the S&P 500 (VOO) significantly in cumulative return. The divergence of -28.8 indicates TGTX's performance is lagging. The relative divergence of 17.8 suggests TGTX is near the lower end of its historical divergence range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR      | MDD   | Alpha    | Beta   | Cap(B) |
|------------|-----------|-------|----------|--------|--------|
| 2015-2017  | -5.0%     | 73.5% | -33.0%   | -0.0   | 1.3    |
| 2016-2018  | -12.0%    | 73.5% | -27.0%   | -0.0   | 0.7    |
| 2017-2019  | 74.0%     | 74.1% | 52.0%    | 0.0    | 1.8    |
| 2018-2020  | 316.0%    | 74.1% | 293.0%   | 0.1    | 8.3    |
| 2019-2021  | 124.0%    | 74.1% | 78.0%    | 0.3    | 3.0    |
| 2020-2022  | -71.0%    | 77.8% | -71.0%   | -0.0   | 1.9    |
| 2021-2023  | -284.0%   | 77.8% | -285.0%  | -1.1   | 2.7    |
| 2022-2024  | 56.0%     | 77.8% | 36.0%    | -1.0   | 4.8    |
| 2023-2025  | 67.0%     | 80.7% | 3.0%     | -0.1   | 4.8    |

**Analysis:**

*   **CAGR:** Wide range of returns, from substantial losses to significant gains, highlighting volatility. Recent years show improvements.
*   **MDD:** Consistently high Maximum Drawdown indicates substantial risk and volatility in the stock.
*   **Alpha:** Indicates performance relative to the benchmark, with periods of both outperformance and underperformance. The most recent period shows Alpha near zero, implying performance similar to the benchmark.
*   **Beta:** Beta is near zero to negative over the period indicating low to inverse correlation with the market.
*   **Cap(B):** Market capitalization in billions, which fluctuates over the period.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 29.93
*   **Last-market Change:** -3.85 (From 31.13)
*   **5-day SMA:** 30.92
*   **20-day SMA:** 31.38
*   **60-day SMA:** 33.11

**Analysis:**

*   The stock price is below all three moving averages (5, 20, and 60-day), suggesting a downtrend. The negative change in the last market day reinforces this trend.

**3. RSI, PPO, and Expected Return**

*   **MRI:** 0.7 (Medium Investment)
*   **RSI:** 31.96 (Approaching Oversold)
*   **PPO:** -0.0399 (Negative)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (32 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 0.8 (+) (Short-term increase)
*   **Expected Return (%):** -127.3% (Significant Negative)

**Analysis:**

*   The MRI suggests a medium investment risk, but the RSI indicates the stock might be approaching oversold conditions, potentially signaling a possible rebound.
*   The negative PPO confirms a downtrend.
*   The hybrid signal suggests buying, which might indicate a potential value play.
*   Despite recent short-term increases in divergence, the expected return is very negative, suggesting a long-term investment could be risky.

**4. Recent News & Significant Events (Yahoo Finance)**

*   **The Earnings Caveat That Sent This Hot Biotech Diving:** Suggests negative investor reaction to a specific detail within an earnings report.
*   **Why TGTX stock is trending among retail traders:** Indicates increased attention, possibly driven by speculative trading or short-term trends.
*   **TG Therapeutics (NASDAQ: TGTX) schedules Dec. 2 fireside chat at Evercore event:** Could be a positive signal, suggesting the company is actively engaging with investors.
*   **TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing:** Mixed outlook, with positive elements in the company's performance but concerns about competitive pressure.
*   **TG Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go?:** Highlights concerns about further price declines.
*   **TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release:** Pre-earnings anticipation, indicating potential positive expectations.

**Analysis:**

Recent news paints a mixed picture. While there's some positive sentiment around earnings expectations and company engagement, there are also clear concerns about competition, earnings caveats, and potential price declines. The stock trending among retail traders can be a double-edged sword, implying volatility.

**4-2) Analyst Opinions**

*   **Mean Rating:** N/A (No Key Provided)
*   **Number of Opinions:** 7
*   **Target Price (avg/high/low):** 44.29 / 60.00 / 13.00
*   **Recent Rating Changes:** No Data

**Analysis:**

The analyst consensus suggests an average price target significantly above the current price, but the wide range (13.00 to 60.00) indicates uncertainty and differing opinions among analysts. The lack of recent rating changes limits the ability to assess the current sentiment.

**5. Recent Earnings Analysis**

| 날짜        | EPS   | 매출        |
|-------------|-------|-------------|
| 2025-11-05  | 2.69  | 0.16 B$     |
| 2025-08-08  | 0.19  | 0.14 B$     |
| 2025-05-09  | 0.03  | 0.12 B$     |
| 2024-11-07  | 0.03  | 0.08 B$     |
| 2025-11-05  | 0.03  | 0.08 B$     |

**Analysis:**

*   The most recent EPS (2.69) is significantly higher than previous quarters, suggesting strong recent performance. Revenue has generally been increasing over the past year, although the duplicate listing of 2025-11-05 needs to be clarified.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.16B    | 82.63%        |
| 2025-06-30   | $0.14B    | 86.58%        |
| 2025-03-31   | $0.12B    | 87.14%        |
| 2024-12-31   | $0.11B    | 85.77%        |
| 2024-09-30   | $0.08B    | 88.86%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-09-30   | $0.61B    | 64.37%   |
| 2025-06-30   | $0.28B    | 10.20%   |
| 2025-03-31   | $0.24B    | 2.13%    |
| 2024-12-31   | $0.22B    | 10.49%   |
| 2024-09-30   | $0.19B    | 2.02%    |

**Analysis:**

*   Revenue has been steadily increasing over the past year.
*   Profit margins are consistently high, indicating strong profitability on revenue.
*   Equity has increased significantly in the most recent quarter.
*   ROE shows significant improvement recently.

**7. Comprehensive Analysis (Summary)**

TG Therapeutics (TGTX) presents a mixed investment picture.

*   **Negative Factors:**
    *   Significant underperformance compared to the S&P 500 (VOO).
    *   High Maximum Drawdown indicating significant risk.
    *   Negative PPO and downtrend in stock price relative to moving averages.
    *   Very negative expected return, suggesting potential long-term losses.
    *   Mixed news flow with concerns about competition and price declines.
*   **Positive Factors:**
    *   Potentially oversold RSI, suggesting a possible rebound.
    *   Recent strong earnings performance (EPS and revenue).
    *   Consistently high profit margins and recent increase in equity.
    *   Analyst average price target above the current price, though with high variability.
*   **Overall:**

    TGTX appears to be a high-risk, high-reward stock. While recent earnings and financial data are positive, significant challenges and uncertainties remain. Investors should be cautious and carefully consider their risk tolerance before investing. The conflicting signals suggest that the stock's future performance is uncertain. More due diligence is required to determine the reasons behind the recent earnings jump and whether it is sustainable.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.